Dr. Antonius Schuh, Chairman of the Board and Chief Executive Officer

Antonius Schuh, Ph.D., age 46, co-founded STI in January 2006 and has served as its Chairman since such time and as its Chief Executive Officer since November 2008. From April 2006 to September 2008 Dr. Schuh served as Chief Executive Officer of AviaraDx, Inc. (now bioTheranostics, Inc., a bioMerieux company), a molecular diagnostic testing  company that is focused on clinical applications in oncology.  From March 2005 to April 2006, Dr. Schuh was Chief Executive Officer of Arcturus Bioscience, Inc. (now part of MDS), a developer of laser capture microdissection and reagent systems for microgenomics.  From December 1996 to February 2005, Dr. Schuh was employed by Sequenom Inc., a publicly traded diagnostic testing and genetics analysis company.  He started with Sequenom as a Managing Director and was promoted to Executive Vice President, Business Development, and from May 2000 to February 2005, served as Sequenom’s President and Chief Executive Officer.  He also previously served as the Head of Business Development at Helm AG, an international trading and distribution corporation for chemical and pharmaceutical products, and in medical and regulatory affairs positions with Fisons Pharmaceuticals (now part of Sanofi-Aventis).  Since March 2009, Dr. Schuh has been appointed to the board of Diogenix, Inc., a privately held molecular diagnostic  company, and since May 2009, Dr. Schuh has served as a director of Transgenomic, Inc., a public biotechnology company focused on genetic analysis and molecular diagnostics.  Dr. Schuh is a certified pharmacist and earned his Ph.D. in pharmaceutical chemistry from the University of Bonn, Germany.

Dr. Henry Ji, Director and Chief Scientific Officer

Henry Ji, Ph.D., age 45, co-founded STI in January 2006 and has served as its Chief Scientific Officer since November 2008 and as a director since January 2006. In 2002, Dr. Ji founded BioVintage, Inc., a research and development company focusing on innovative life science technology and product development and has served as its President since 2002.  From 2001 to 2002 Dr. Ji served as Vice President of CombiMatrix Corporation, a publicly traded biotechnology company developing and offering technologies applicable in drug development, genetic analysis and molecular diagnostics.  During his tenure at CombiMatrix, Dr. Ji was responsible for strategic technology alliances with biopharmaceutical companies.  From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as Vice President, of Stratagene Corporation (acquired by Agilent Technologies, inc.) a company that develops innovative products and technologies for life science research, where he was responsible for technology development and product licensing.  In 1997, Dr. Ji co-founded Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Before, Dr. Ji was a research scientist with Human Genome Sciences, Inc. Dr. Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of STI’s intellectual property.  Dr. Ji has a Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University, China.

Richard G. Vincent, Chief Financial Officer

 Mr. Vincent, age 46, has over 20 years of accounting experience and previously served as the Company’s Vice President, Finance since January 2010. Since April 2008, Mr. Vincent has also served as a contract Chief Financial Officer for various other companies, including: Meritage Pharma, Inc., Elevation Pharmaceuticals, Inc., Verus Pharmaceuticals, Inc., and Chumby Industries, Inc. From October 2004 to March 2009, Mr. Vincent served as Chief Financial Officer of Verus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing pediatric drug/device combination products for the treatment of asthma, allergies, and related diseases and conditions. From October 2003 to October 2004, Mr. Vincent served as Chief Financial Officer of Women First HealthCare, Inc., a public specialty pharmaceutical company focused on women’s healthcare and dermatology. Mr. Vincent also served as Senior Director of Finance for Elan Pharmaceuticals, Inc., a public biopharmaceutical company engaged in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain, from October 2001 to October 2003. From November 1995 to October 2001, Mr. Vincent served in various senior management capacities for several wireless and technology companies. From 1987 to 1995, Mr. Vincent held a number of positions with Deloitte & Touche LLP, the last of which was senior manager, where he specialized in emerging growth and publicly-reporting companies. Mr. Vincent’s experience includes raising over $400 million through venture capital, major commercial banks and institutions, and public offering proceeds for high growth pharmaceutical and technology based companies, and participating in a number of acquisitions and divestitures valued at over $500 million.